循环microRNA-483作为IGF-II相关非胰岛细胞肿瘤低血糖症生物标志物的潜在价值
研究纳入145例疑似非胰岛细胞肿瘤低血糖症(NICTH)病例,其中100例经血清大分子IGF-II检测确诊,并分析25例确诊NICTH术后血清及11例孤立性纤维瘤(SFT)组织。结果显示血清miR-483-5p对NICTH的诊断能力优于IGF-II及IGF-II/IGF-I比值,且术后随大分子IGF-II消失而显著下降。
要点
- 血清miR-483-5p对NICTH的诊断能力优于血清IGF-II及IGF-II/IGF-I比值。
- NICTH患者肿瘤切除后血清miR-483-5p水平随大分子IGF-II消失而显著下降。
- SFT组织中miR-483-5p和-3p表达水平显著高于手术切缘组织。
核心结论
- 循环miR-483-5p来源于产生IGF-II的肿瘤,作为NICTH诊断和治疗结局的生物标志物似乎比IGF-II或IGF-II/IGF-I比值更可靠。
- 这些发现突显了miR-483-5p在NICTH管理中的临床效用。
研究设计与样本
- 研究对145例疑似NICTH的血清以及25例确诊NICTH手术病例的术后血清进行了蛋白质印迹分析、IGF-II酶联免疫吸附测定以及miR-483-5p和-3p的定量聚合酶链反应分析。
- 研究比较了11例手术病例中切除的孤立性纤维瘤(SFT)组织与其周围切缘组织的miR-483表达水平。
主要发现
- 145例疑似NICTH病例中,100例基于血清大分子IGF-II检测确诊为NICTH。
- 受试者工作特征曲线分析显示,血清miR-483-5p对NICTH的诊断能力优于血清IGF-II或经典诊断标志物IGF-II/IGF-I比值。
- 手术肿瘤切除后,随着大分子IGF-II消失,血清miR-483-5p水平显著下降。
- 切除的SFT组织中miR-483-5p和-3p表达水平显著高于其手术切缘组织。
关键数值与推荐
- 145例疑似NICTH病例中100例经血清大分子IGF-II检测确诊。
- 血清miR-483-5p对NICTH的诊断能力优于血清IGF-II及IGF-II/IGF-I比值。
- 25例确诊NICTH手术病例术后血清miR-483-5p水平随大分子IGF-II消失而显著下降。
- 11例手术病例中,SFT组织miR-483-5p和-3p表达水平显著高于手术切缘组织。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In most cases of non-islet cell tumor hypoglycemia (NICTH), high molecular weight forms of insulin-like growth factor II, commonly referred to as big IGF-II, cause hypoglycemia. MicroRNA-483 (miR-483), encoded within an intron of IGF2, has been suggested to be coexpressed with IGF-II. OBJECTIVE: The aim of this study is to demonstrate the utility and reliability of circulating miR-483 as a biomarker for diagnosis and therapeutic outcome of NICTH. METHODS: Sera from 145 cases of suspected NICTH, and postoperative sera from 25 surgical cases of confirmed NICTH were subjected to Western blot analysis and enzyme-linked immunosorbent assay for IGF-II and quantitative polymerase chain reaction analysis for miR-483-5p and -3p. Tissue miR-483 expression levels were compared between resected solitary fibrous tumors (SFTs) and their surrounding margins from 11 surgical cases. RESULTS: NICTH was confirmed in 100 out of 145 cases based on the detection of big IGF-II in their sera. Receiver operating characteristic curve analysis revealed that serum miR-483-5p had a better diagnostic ability for NICTH than serum IGF-II or the classical diagnostic marker the IGF-II to IGF-I ratio. Notably, serum miR-483-5p levels decreased significantly with the disappearance of big IGF-II after surgical tumor resection. Tissue miRNA-483-5p and -3p expression levels were significantly higher in resected SFT tissues than in their surgical margins. CONCLUSION: Circulating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.
引用
- Okazaki-Hada M, Nagao M, Asai A, et al. Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II-Associated Non-Islet Cell Tumor Hypoglycemia. J Clin Endocrinol Metab. 2025. PMID: 39689018. doi:10.1210/clinem/dgae879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。